Investor Relations

Press Releases

14 Nov '23

Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash

REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has

10 Aug '23

Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update

Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing

03 Aug '23

Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that

02 Aug '23

Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)

REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced

Excellence at the Point of Care

Corporate Profile

Stock Information

Press Releases

Recent Events

Rob Kelley

Chief Executive Officer

Andrew A. Lukowiak, Ph.D.

President & Chief Scientific Officer

Becky Markovich

Interim Chief Financial Officer

Excellence at the Point of Care

Corporate Profile

Stock Information

Press Releases

Recent Events

Executive Team

Rob Kelley

Chief Executive Officer

Andrew A. Lukowiak, Ph.D.

President & Chief Scientific Officer

Becky Markovich

Interim Chief Financial Officer